Raymond James & Associates Ionis Pharmaceuticals Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Raymond James & Associates holds 22,524 shares of IONS stock, worth $866,273. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,524

Previous 23,573 4.45%

Holding current value

$866,273

Previous $1.12 Million 19.68%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$40.06 - $51.86 $42,022 - $54,401	-1,049 Reduced 4.45%	22,524 $902,000
Q2 2024 Jul 19, 2024	SELL	$36.45 - $47.7 $3.24 Million - $4.24 Million	-88,981 Reduced 79.06%	23,573 $1.12 Million
Q1 2024 Apr 22, 2024	SELL	$42.03 - $53.55 $2.99 Million - $3.81 Million	-71,122 Reduced 38.72%	112,554 $4.88 Million
Q4 2023 Jan 16, 2024	SELL	$43.39 - $51.63 $475,250 - $565,503	-10,953 Reduced 5.63%	183,676 $9.29 Million
Q3 2023 Oct 24, 2023	BUY	$38.5 - $47.13 $105,682 - $129,371	2,745 Added 1.43%	194,629 $8.83 Million
Q2 2023 Jul 25, 2023	SELL	$34.73 - $43.33 $315,001 - $393,003	-9,070 Reduced 4.51%	191,884 $7.87 Million
Q1 2023 Apr 14, 2023	SELL	$33.58 - $41.2 $823,247 - $1.01 Million	-24,516 Reduced 10.87%	200,954 $7.18 Million
Q4 2022 Feb 08, 2023	SELL	$37.12 - $46.52 $471,349 - $590,710	-12,698 Reduced 5.33%	225,470 $8.52 Million
Q3 2022 Oct 25, 2022	SELL	$36.54 - $48.66 $302,587 - $402,953	-8,281 Reduced 3.36%	238,168 $10.5 Million
Q2 2022 Aug 12, 2022	SELL	$31.71 - $43.0 $325,883 - $441,911	-10,277 Reduced 4.0%	246,449 $9.12 Million
Q1 2022 May 11, 2022	SELL	$29.88 - $37.04 $37,618 - $46,633	-1,259 Reduced 0.49%	256,726 $9.51 Million
Q4 2021 Feb 08, 2022	SELL	$25.61 - $35.1 $1.11 Million - $1.53 Million	-43,464 Reduced 14.42%	257,985 $7.85 Million
Q3 2021 Nov 02, 2021	BUY	$33.54 - $40.55 $251,918 - $304,571	7,511 Added 2.56%	301,449 $10.1 Million
Q2 2021 Aug 11, 2021	SELL	$34.54 - $47.25 $281,051 - $384,473	-8,137 Reduced 2.69%	293,938 $11.7 Million
Q1 2021 May 14, 2021	SELL	$42.51 - $63.78 $193,803 - $290,773	-4,559 Reduced 1.49%	302,075 $13.6 Million
Q4 2020 Feb 12, 2021	SELL	$45.3 - $60.27 $2.53 Million - $3.36 Million	-55,795 Reduced 15.39%	306,634 $17.3 Million
Q3 2020 Nov 04, 2020	BUY	$47.45 - $62.95 $429,659 - $570,012	9,055 Added 2.56%	362,429 $17.2 Million
Q2 2020 Jul 28, 2020	SELL	$46.85 - $61.05 $52,940 - $68,986	-1,130 Reduced 0.32%	353,374 $20.8 Million
Q1 2020 Apr 21, 2020	SELL	$41.6 - $63.4 $14.5 Million - $22.1 Million	-348,470 Reduced 49.57%	354,504 $16.8 Million
Q4 2019 Feb 12, 2020	SELL	$53.85 - $65.27 $1.61 Million - $1.95 Million	-29,830 Reduced 4.07%	702,974 $42.5 Million
Q3 2019 Nov 07, 2019	SELL	$59.06 - $72.15 $2.14 Million - $2.61 Million	-36,156 Reduced 4.7%	732,804 $43.9 Million
Q2 2019 Aug 06, 2019	SELL	$62.09 - $86.14 $1.64 Million - $2.27 Million	-26,357 Reduced 3.31%	768,960 $49.4 Million
Q1 2019 May 06, 2019	BUY	$52.92 - $81.17 $611,649 - $938,162	11,558 Added 1.47%	795,317 $64.6 Million
Q4 2018 Feb 11, 2019	SELL	$43.37 - $59.54 $1.24 Million - $1.7 Million	-28,609 Reduced 3.52%	783,759 $42.4 Million
Q3 2018 Nov 14, 2018	SELL	$42.88 - $53.7 $1,029 - $1,288	-24 Reduced -0.0%	812,368 $41.9 Million
Q2 2018 Aug 14, 2018	BUY	$40.53 - $50.7 $998,010 - $1.25 Million	24,624 Added 3.13%	812,392 $33.9 Million
Q1 2018 May 14, 2018	BUY	$44.08 - $55.05 $454,861 - $568,060	10,319 Added 1.33%	787,768 $34.7 Million
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $25,150 - $32,195	500 Added 0.06%	777,449 $39.1 Million
Q3 2017 Nov 13, 2017	BUY	$45.56 - $59.57 $498,289 - $651,517	10,937 Added 1.43%	776,949 $39.4 Million
Q2 2017 Aug 14, 2017	BUY	N/A	766,012	766,012 $39 Million

Others Institutions Holding IONS

# of Institutions

386

Shares Held

125M

Call Options Held

2.19M

Put Options Held

510K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.46B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Ionis Pharmaceuticals Inc Transaction History